Insiders At Denali Therapeutics Sold US$1.8m In Stock, Alluding To Potential Weakness
Denali Therapeutics Upgraded to Buy From Hold at Stifel
Stifel Upgrades Denali Therapeutics(DNLI.US) to Buy Rating, Raises Target Price to $37
Stifel Upgrades Denali Therapeutics to Buy, Announces $37 Price Target
Denali Therapeutics Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After Announcing on Thursday It Began Its Phase 2a Study of LRRK2 Inhibitor BIIB122 for LRRK2-associated Parkinson's Disease With Its First Participant Dosed.
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
